SOD-1 xCas12i/Cas13Y gene therapy (HuidaGene Therapeutics)

N/A

Report date: 2025/01/26 17:05:44
NME

Base Information

Drug NameSOD-1 xCas12i/Cas13Y gene therapy (HuidaGene Therapeutics)
Drug Alias NameAAV-hfCax12Max-SOD1 gRNAAAV-hfCas13Y-SOD1 gRNA
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionSuperoxide dismutase inhibitors
TargetsSuperoxide dismutase
Therapy Area/IndicationsAmyotrophic Lateral SclerosisNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuidaGene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuidaGene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A